Alexandria Real Estate Equities, Inc.
Can Alexandria refill vacating lab space and lease its development pipeline fast enough to offset a five-year biotech downturn while selling assets to fund the gap?
Last 4 earnings calls · through Q2 FY2026
Bull case
Cluster dominance in leasing
The bull case is that Alexandria owns the lab clusters where tenants have to be, so it captures far more than its share of every lease signed in its markets.
Biotech funding recovery
It also bets that capital is returning to biotech tenants, which management says is showing up in venture funding, public offerings and mid-sized space requirements.
Self-funded capital plan
Management intends to fund construction and debt paydown by selling land and partial interests rather than issuing shares, which protects per-share results.
Advanced technology demand
Tenant demand is broadening beyond biotech into advanced technology users who need secure, heavy-infrastructure buildings and pay for much of their own fit-out.
Bear case
Public biotech demand gap
The bear case is that the tenants who anchor the portfolio are not expanding, and market share cannot fix a shrinking pool of laboratory demand.
Oversupplied lab submarkets
Competing landlords built heavily during the boom, so Alexandria has to win leases with free rent and large build-out allowances that depress returns.
Known lease move-outs
A block of large leases comes back with long expected downtime, so occupancy keeps falling even while new leasing activity improves.
Asset sale timing
Asset sales have slipped later in the year, leaving leverage well above the stated target and forcing a dividend reset to keep cash inside the business.
Bull and bear points
Growth & Execution
In short: Leasing wins a larger share of its markets, while expiring space carries long downtime before it is refilled.
Alexandria leases well above its share of each market
Capturing twice or more of the leasing done in its largest markets means tenants keep choosing its buildings even while competitors' space sits empty.
Q2 FY2026 callSpace already leased starts paying rent in November
About 1.4 million square feet of vacant space is signed and scheduled to commence in November 2026, adding roughly $69 million of annual rental revenue.
Q2 FY2026 callPublic biotech leasing returns from zero
A quarter ago management reported no public biotech leases at all and called it unprecedented; that segment is now back to about 6% of leasing volume.
Tone shiftQ1 FY2026 → Q2 FY2026
2027 expirations face 12 to 24 months of downtime
Roughly 1.4 million square feet carrying $100.5 million of rent comes back in 2027 and is expected to sit empty for a year or more, pushing any earnings recovery further out.
Q2 FY2026 callOccupancy guidance was cut again as space empties
Management lowered its year-end 2026 occupancy midpoint to 87% from 88.5%, and revenue fell 13% year over year in the second quarter as tenants moved out faster than space was refilled.
Q1 FY2026 call
Profitability & Financial Strength
In short: Costs are low and debt maturities are long, while free cash flow is negative and leverage sits above target.
General and administrative costs run near half the REIT average
G&A is about 6.6% of net operating income, and management expects roughly $76 million of cumulative savings across 2025 and 2026 versus its 2024 base.
Q2 FY2026 callLongest debt maturity among S&P 500 REITs
Average remaining debt term is 9.7 years and the $5 billion credit line now runs to 2032, so refinancing risk is spread far into the future.
Q2 FY2026 callAsset sales already cover most of the funding plan
46% of the $2.9 billion capital target is completed or pending and another 38% is in process, and guidance assumes no common equity issuance this year.
Q2 FY2026 call
Free cash flow stays negative while construction continues
Free cash flow was negative $460 million over the last twelve months because construction and leasing costs outrun the cash the properties produce.
Filed financialsLeverage runs above the stated target range
Net debt is $14.3 billion and second-quarter leverage was 7x, above the 5.6x to 6.2x year-end goal, and it falls only as sales close.
Q2 FY2026 callThe dividend was cut 45% to hold cash
The quarterly payout was reduced by $0.60 per share in December 2025 to keep cash for construction and debt paydown, cutting the distribution REIT owners rely on.
10-K, filed 2026-01-26
Market Position
In short: Its Megacampus clusters beat local occupancy, but public biotech tenants are barely leasing space.
Megacampus portfolio leases at a premium to its markets
Megacampuses are 80% of annual rent and run 8 to 12 points above market occupancy in the three largest markets, which supports pricing as leases renew.
Q2 FY2026 callCourt defeat of the NIH indirect cost cap
The 15% limit on reimbursement of institutional indirect costs was struck down, restoring a source of demand from academic and institutional tenants in its markets.
Q1 FY2026 callAdvanced technology tenants fill lab-ready buildings
Users needing high power, heavy floor loads and secure space are signing at 311 Arsenal and 3000 Minuteman, converting chronic vacancy with less capital than a lab conversion.
Q2 FY2026 call
Public biotech is 21% of rent but 6% of leasing
Public biotech companies cannot raise money without data or a milestone, so they are not taking space even as the sector index rises, leaving a core tenant group inactive.
Q2 FY2026 callCompeting supply forces free rent and build-out spending
Other developers built laboratory space during the boom, and management says winning leases now requires larger tenant improvement packages and more free rent than before.
Q2 FY2026 callThe recovery call moved from finding a bottom to years out
Management once said it was watching the bottom form; it now assumes 12 to 24 months of downtime on vacated space and says it will stay cautious until public biotech demand returns.
Tone shiftQ3 FY2025 → Q2 FY2026